The well-funded biotech lost most of its value after its drug flunked a late-stage trial. One analyst described the results ...

CNBC’s Angelica Peebles joins 'Power Lunch' to discuss Neumora's depression drug failing its trial results. Stacey Plaskett’s ...

Neuroscience company Neumora Therapeutics (NMRA) announced today that its experimental treatment for depression, Navacaprant, ...

The study, first of the three late-stage trials, was testing the drug, navacaprant, in patients with major depressive ...

Neumora Therapeutics Inc.’s shares plummeted after the company’s experimental drug failed to show a benefit in a final-stage ...

Patients who received the drug, called navacaprant, showed no more improvement in depressive symptoms than people who ...

Neumora's KOASTAL-1 study results show navacaprant missed key goals in major depressive disorder. Additional studies and ...

Neumora Therapeutics Inc. (NASDAQ: NMRA) nosedived by more than 80 percent during pre-market trading following disappointing ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Happy New Year, biotech ...

Discover why psychiatrists are moving beyond single-treatment approaches and how combining therapies could be the key to ...

Even the coroner specified that the self-inflicted death was an “adverse effect” of the antidepressant the man had been ...

Argentine police on Jan 3 arrested one of the two men accused of supplying drugs to British singer Liam Payne before he fell ...